Podcasts about pharmaceuticals

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“Climate change is the biggest health threat of our century, so we need to train clinicians for a future where it will alter disease patterns, the demand on health systems, and how care is delivered,” says Dr. Sandro Demaio, director of the WHO Asia-Pacific Centre for Environment and Health, underscoring the stakes behind the organization's first regionally-focused climate and health strategy. The five-year plan Dr. Demaio is leading aims to help governments in 38 countries with 2.2 billion people manage rising heat, extreme weather, sea-level change, air pollution and food insecurity by adapting health systems, protecting vulnerable populations, and reducing emissions from the healthcare sector itself. In this timely interview with Raise the Line host Michael Carrese, Dr. Demaio draws on his experiences in emergency medicine, global public health, pandemic response and climate policy to argue for an interconnected approach to strengthening systems and preparing a healthcare workforce to meet the heath impacts of growing environmental challenges. This is a great opportunity to learn how climate change is reshaping medicine, public health and the future of care delivery.  Mentioned in this episode: WHO Asia-Pacific Centre for Environment and Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.January was set to be the first month of a new 340B rebate pilot program, marking a seismic shift in how the drug discount program functions. But a flurry of court activity just before and after the new year put a sudden pause on the rebate program and left the future of the rebate pilot in question. Amanda Nagrotsky, vice president of legal and policy with 340B Health, joins the show to fill us in on the latest.HRSA Pauses Rebate Implementation After Court RulingIn late December, a federal court in Maine issued a ruling that temporarily blocks the Health Resources & Services Administration (HRSA) from moving forward with the 340B rebate pilot. HRSA then announced it was pausing the pilot and instructed drug companies to continue providing 340B pricing through the traditional upfront discount model. Nagrotsky says the judge found that hospitals had demonstrated a high likelihood of irreversible harm if rebates went forward.Government Appeals, Then ReconsidersImmediately after the ruling, HRSA unsuccessfully argued to the Maine court and an appeals court that the agency still should be able to implement the 340B rebate pilot program while it appealed the initial ruling. After the courts denied that request, the government agreed to voluntarily dismiss its appeal and said it would reconsider its rebate program approvals. Nagrotsky stresses that it is unclear what this means. It could mean the government might overhaul or scrap the rebate program, or it might issue revised approval notices to better explain the rebates' purpose and address concerns of potential harm to 340B hospitals.Medicare Maximum Fair Price Provisions Still Take EffectDespite the legal questions surrounding the 340B rebate pilot program, new Medicare maximum fair price (MFP) provisions did take effect at the beginning of January for the drugs that would have been subject to the rebates. Nagrotsky says that while 340B still can be used for these drugs, covered entities are not entitled to MFP refunds from drug companies in those scenarios. She recommends hospitals closely track expected MFP rebates to identify any missing refunds for claims that did not use 340B drugs.ResourcesDismissal of Appeal Sets Stage for HRSA Reconsideration of 340B Rebates

We have a special episode of Raise the Line on tap today featuring the debut of host Dr. Parsa Mohri, who will now be leading our NextGen Journeys series that highlights the fresh perspectives of learners and early career healthcare professionals around the world on education, medicine, and the future of care. Parsa was himself a NextGen guest in 2024 as a medical student at Acibadem University in Turkey. He's now a general physician working in the Adult Palliative Care Department at Şişli Etfal Research and Training Hospital in Istanbul.  Luckily for us, he's also continuing in his role as a Regional Lead for the Osmosis Health Leadership Initiative (OHLI). For his first guest, Parsa reached out to a former colleague in the Osmosis family, Negeen Farsio, who worked with him as a member of OHLI's predecessor organization, the Osmosis Medical Education Fellowship. Negeen is now a graduate student in medical anthropology at Brunel University of London, a degree which she hopes will inform her future work as a clinician. “Medical anthropology is a field that looks at healthcare systems and how human culture shapes the way we view different illnesses, diseases, and treatments and helps you to see the full picture of each patient.” You are sure to enjoy this heartfelt conversation on how Negeen's lived experience as a patient and caregiver have shaped her commitment to mental health and patient advocacy, and how she hopes to marry humanity with medicine in a world that yearns to heal. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

New research is transforming the outlook for cervical and uterine cancers -- two of the most serious gynecologic malignancies worldwide – and we'll be hearing from one of the people shaping that progress, Dr. Mary McCormack, on this episode of Raise the Line. From her perch as the senior clinical oncologist for gynecological cancer at University College London Hospitals, Dr. McCormack has been a driving force in clinical research in the field, most notably as leader of the influential INTERLACE study, which changed global practice in the treatment of locally advanced cervical cancer, a key reason she was named to Time Magazine's 2025 list of the 100 most influential people in health. “In general, the protocol has been well received and it was adopted into the National Comprehensive Cancer Network guidelines which is a really big deal because lots of centers, particularly in South and Central America and Southeast Asia, follow the NCCN's lead.”In this conversation with host Michael Carrese, you'll learn about how Dr. McCormack overcame recruitment and funding challenges, the need for greater access to and affordability of treatments, and what lies ahead for women's cancer treatment worldwide. Mentioned in this episode:INTERLACE Cervical Cancer Trial If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Unleashed! The Political News Hour with Mayor Deb – Pharmaceuticals dominate modern healthcare while questions about safety, consent, and accountability remain discouraged. I explore the historical roots of pharmakeia, examine legal protections shielding the industry, and share Dr. Stephanie Coxon's experience to challenge vaccine taboos, defend parental rights, and expose a system where profit masquerades as healing...

In this episode of the Tick Boot Camp Podcast, Dr. Eric D. Gordon — globally recognized expert in Lyme disease, ME/CFS, mold toxicity, MCAS, mitochondrial dysfunction, and complex chronic illness — explains why chronic illness is never caused by a single factor and why recovery requires a strategic “order of operations.” Recorded after meeting at Project Lab Coat during NYFW, this conversation dives into chronic inflammation, immune dysregulation, why some people stay sick for years, why certain treatments backfire, how metabolomics reveals dysfunction that standard tests miss, and the future of individualized chronic illness care. Guest Bio Medical Director, Gordon Medical Associates, and President, Gordon Medical Research Center Dr. Gordon has 45+ years of experience treating the most complex chronic illness cases. He specializes in: Lyme disease and tick-borne infections ME/CFS and post-infectious illness Mold and mycotoxin exposure Mast Cell Activation Syndrome (MCAS) Autoimmune disease Environmental illness Mitochondrial dysfunction and metabolic collapse He co-authored the landmark 2016 PNAS metabolomics study with Dr. Robert Naviaux, which reshaped global understanding of ME/CFS and chronic inflammatory diseases. Key Topics Covered How Dr. Gordon became one of the world's leading chronic illness clinicians Why patient belief and validation are foundational to healing Why chronic illness cases don't fit conventional medical models Why herbs often worsen symptoms in MCAS or inflamed patients When pharmaceuticals help stabilize sensitive patients How chronic inflammation blocks trace mineral absorption The link between minerals, B vitamins, mitochondria, and NAD/NADH When detoxification helps — and when it causes more harm How childhood infections and environment shape lifelong immunity The massive impact of modern microbiome disruption Mold illness as the “great derailer” of Lyme treatment Why genetics like MTHFR and HLA are not destiny Why some people heal from Lyme without treatment How metabolomics and AI will usher in precision medicine What actually keeps people sick — accumulated compensations, not the tick bite What intuitive patients get right (and wrong) about their symptoms Timestamps 0:02 – Meeting Dr. Gordon at Project Labcoat 1:08 – Who he is and how he entered complex illness medicine 2:30 – Realizing conventional medicine fails chronic patients 5:45 – Why chronic illness doesn't fit standard algorithms 8:10 – Herbs vs antibiotics: what most people misunderstand 11:28 – Inflammation and why sensitive patients react to everything 13:45 – MCAS and immune overactivation 16:25 – Why herbal formulas can trigger flares 19:30 – Pharmaceuticals that calm inflammation 20:50 – Trace minerals, mitochondrial function, and NAD pathways 23:55 – Why standard labs can't see cellular dysfunction 26:10 – How childhood immune experiences shape resilience 28:40 – Environmental changes and microbiome decline 30:30 – Shoes, posture, fascia, lymphatics 36:35 – Structural healing and hypersensitive patients 41:20 – Founding Gordon Medical Associates 43:00 – Early discoveries with Lyme disease patients 48:30 – Detoxification, herbal protocols, and mold models 52:10 – Mold's ability to halt all progress 55:30 – Why mold affects some family members and not others 57:20 – How food supply antibiotics disrupt immunity 59:50 – Genetics are possibilities, not fate 1:03:20 – Why some people recover after a tick bite and others don't 1:07:00 – How AI and metabolomics will transform treatment 1:10:40 – Genes vs environment 1:13:30 – Chronic illness requires many small steps 1:16:00 – How to work with Dr. Gordon 1:18:30 – Final message of hope Pull Quotes “Chronic illness is not caused by one thing — and it's never healed by one thing.” “Herbs depend on your body's ability to modulate inflammation. If you can't dampen the fire, herbs feel like gasoline.” “Genetics are not destiny. They're possibilities.” “Mold makes every other treatment look like it's failing.” “You can absolutely get well — but there is no single magic bullet.” Call to Action If this episode brought you clarity or hope, please share it with someone navigating chronic Lyme, mold illness, MCAS, or ME/CFS. Subscribe and leave a review to help more people find this conversation and believe that healing is possible.

When I first conceived of my theory of everything named “A Simple Explanation of Absolutely Everything” back in 2008, I was unfamiliar with Gnosticism. A Simple Explanation of Absolutely Everything is presented in secular terms, using common concepts from all fields of human endeavor from math and science on through religion, psychology, and sociology. In A Simple Explanation of Absolutely Everything, God is usually referred to as Metaversal Consciousness, and we here on this plane carry that consciousness forward into this life as Units of Consciousness. A Simple Explanation of Absolutely Everything was written to appeal to folks who usually don't go in for religion but who, nonetheless, are seeking an overall structure for understanding the mysteries of life. I updated A Simple Explanation of Absolutely Everything in 2020 to make it smaller and converted the color images to black and white to make it less expensive to purchase. The 2020 edition is also available in kindle and audible. Had I been a philosophy major like my brother, Dr. Bill Puett, I would have known the names for various aspects of the Simple Explanation of Absolutely Everything, like panpsychism and monadism. I would have been familiar with works such as Huxley's Perennial Philosophy. But I wasn't a philosophy major. I am instead a psychologist with a Ph.D. in Classical Rhetoric. My field of deep study is ancient texts and ideologies, and these are what influenced the development of my theory, not modern philosophers such as Leibniz or Kant. So rather than kludge together other people's ideas, which is the normal way that scholars work, I built the Simple Explanation of Absolutely Everything from the ground up using my own observation and logic. And then around 2016, I read a copy of the Nag Hammadi Scriptures. At first I found the ideas shocking. These were the very heresies my conservative Christianity had warned me away from. According to Christians, these beliefs were excluded from our modern versions of the Bible to protect the church from theological misinformation. I discovered that radical repackaging had removed from the New Testament a type of spiritual belief that was well- known to Jesus and his followers. This belief system, commonly called Gnosticism, describes Christianity differently than does our modern Church. Gnosticism makes sense of most of the more mysterious aspects of Christianity, including humanity's role in the great scheme of things, and common questions such as “why is there evil in the world?” Many of these answers to longstanding theological problems were resurrected along with the Nag Hammadi scriptures when they were rediscovered and exhumed from the desert sands in 1945. I learned that the Nag Hammadi scriptures had been buried deep in the Egyptian desert around 350 AD, preserving them from the great Biblical purge conducted by the Council of Nicene at the behest of the Catholic Pope and the Emperor of Rome as they shaped and packaged Christianity to suit their needs. Keep in mind that these ancient teachings have been held back from almost 2000 years of formal study and Christian theology. So what you are about to learn from the Nag Hammadi scriptures is fresh, clean, and unsullied by centuries of scholastic and theological opinions. Over the next couple of years I carefully picked up the Nag Hammadi and I set it back down numerous times, lest I be led astray by false beliefs. Eventually I narrowed my focus to one of the codices in particular that seemed to accord most closely with my understanding of the teachings of Jesus. This book is called The Tripartite Tractate, which simply means the 3-part book. The “3” also refers to the 3-part nature of humanity: spiritual, psychological, and material. I spent time conducting a word study on the Tripartite Tractate, attempting to nail down some very confusing, archaic language. I also made diagrams and illustrations of the ideas presented in the book as I read. Then I put the material away for another year to let it rest and percolate. Finally, in 2019, I wrote and published a small book called The Gnostic Gospel Illuminated, based upon the Tripartite Tractate. The purpose of The Gnostic Gospel Illuminated is to present the gnosis of the Tripartite Tractate as simply and clearly as possible. The format of the Gnostic Gospel book is similar to the Chick cartoon tracts I used to hand out during my Jesus-freak days in the late 1960s. Each concept in the Gnostic Gospel is illustrated by my own original artwork that converts difficult ideas from the Tripartite Tractate into easy-to-understand drawings. With my simple Gnostic Gospel, anyone, of any level of education, can grasp Gnostic theology. Since that time, I have continued to develop the Gnostic theology as presented in the Tripartite Tractate through my Gnostic Insights podcast. I have also had the pleasure of presenting this Gnostic theology as a guest on numerous podcasts hosted by others. The book, A Simple Explanation of the Gnostic Gospel, represents the current state of my personal gnosis within the context of a fully developed Gnostic theology. Although The Gnostic Gospel Illuminated presents everything one needs to know to remember the gnosis they were born with, A Simple Explanation of the Gnostic Gospel goes beyond The Gnostic Gospel Illuminated to explain, as simply as humanly possible, the why's and wherefores of gnosis. Before we go any further let's answer the question: what is gnosis? We keep talking about gnosis and Gnosticism, but what does this mean? Gnosis simply means knowing. And in the gnostic frame of reference, gnosis refers to remembering the truth of our existence and our origin. Gnostic literature says we come into life holding all of this knowledge within ourselves and we have complete access to the Father, the Son, and the Fullness at any time that we turn our focus upward. It is this direct conduit to the Father that brings us into alignment with our gnosis. Gnosis is a Greek word. Another word related to gnosis is anamnesis. You know that the word amnesia means forgetting. Anamnesis means not forgetting. So the process of coming to gnosis is a process called anamnesis—or remembering. Just to let you know, this book sometimes throws around big words like anamnesis. Not to worry though, because the goal here is to explain these words clearly enough so you will be able to understand them without running to the dictionary. Many people claim that it is impossible to know or describe the full glory of the transcendent, immortal Father due to our own human limitations. After all, how could limited beings such as ourselves possibly imagine the greatness of the originator of the universe, much less our place in the grand design? Wouldn't lesser beings reflect a diminished view of God? Wouldn't these lesser beings be limited to offering a tarnished glory that falls far short of the object of their praise? The Tripartite Tractate, the book of the Nag Hamadi that I use as my primary source material, puts it this way: “If the members of the ALL had risen to give glory according to the individual powers of each, they would have brought forth a glory that was only a semblance of the Father, who himself is the ALL. Thus creation would have been doomed from the outset to never comprehend the full glory of either the Father or itself.” According to the Gnostic Gospel, the Father realized the impossibility of his creation comprehending himself and so the Father built a helpful workaround meant to aid comprehension through selfless union and cooperation with others in a shared task. “For that reason, they were drawn into mutual intermingling, union, and oneness through the singing of praise from their assembled fullness. They were one and, at the same time, many, accurately reflecting the One who himself is the entirety of the ALL out of perfect union with itself and with the Son, and by means of a single shared effort, the ALL gave glory to the eternal one who had brought it forth.” We will learn all about the Father, the Son, and the ALL in the order that Creation itself came from the Father. I like to begin with the cosmos as it unfolded and rolled out. The word for that sort of study is “cosmogony,” which is the study of the origins of the universe. This makes the most sense to me–to start at the very beginning and then to go through the entire process of how everything came to be and who the principle players are and then, after that is established, to see how that applies to our lives. Then we can ask, “Why are we here? Is there a purpose to our lives? How should we live?” After that, we can finally consider the final roll-up of the universe and what happens after we die. All of these questions are answered very precisely in the Tripartite Tractate of the Nag Hammadi. This knowledge is “gnosis.” Valentinian Gnosticism is a form of Christianity, and I maintain that it is the true form of Christianity that Christianity should be. It is my understanding that this wisdom would have been what Jesus was actually talking about, and that's why the New Testament is consistent with what I have been teaching. When Jesus said, “I and my Father are One,” he was talking about the gnostic God Above All Gods. So you are not wandering into deep heresy by exploring Valentinian Gnosticism. However, if you are a Christian, you should know that there are indeed a couple of major heresies in Gnosticism. One major heresy, and this is a big heresy, is that that the Creator God of this universe that we've been calling Jehovah or Yaweh is not the God Above All Gods. Yes, Jehovah is the creator of the heavens and earth. But his creation only extends to the mineral level. Basically, Jehovah is in charge of all the material in the universe. Jehovah makes our material universe hold its shape and appear solid. So, yes, Jehovah as the Creator God of our material universe is in line with Christianity. But Gnosticism then goes on to say that the creator of this universe is not the Father, but a fallen entity. The Creator God is an Aeon who fell from the Fullness of God. In the Tripartite Tractate the Aeon who fell is named Logos. Another big heresy in gnostic Christianity is the notion that everyone will be redeemed. As our Christian New Testament repeatedly says, redemption is not based upon merit or works. It is not based upon rituals such as baptism and communion . Redemption is based upon the fact that Christ came to Earth and it was the Christ's job to redeem us all, not ours. So it doesn't matter what you think about Christ. It doesn't matter whether you believe in redemption or not, because your beliefs and actions do not limit the ability of Christ to accomplish his mission. I don't see universal redemption as the negative heresy it is made out to be. I actually find it empowers the role of Christ more than our modern church doctrine. It makes Jesus even more important because everyone is redeemed. Everyone who ever was, everyone who lives now, and everyone who will ever be is covered by the redemption of Christ, because it is Christ's job to do that and the Christ accomplished his job. This fact is actually stated throughout the New Testament, although generally misinterpreted. It doesn't matter whether you hold out as an atheist. The thing is, when you do hold out, when you refuse to acknowledge the mission of the Christ, then it's a pretty good indication that you are not in tune with the Father, because the Christ is the emissary of the Father. So if you reject the redemption of the Christ, you are rejecting the Father. If you love the Father, then you will love the Son. And if you love the Son, you will love the Christ. Sounds pretty Christian to me. Valentinian Gnosticism is most assuredly not a New Age religion. The books of the Nag Hammadi were written on sheepskin parchment and buried in a clay jar in the desert for 2000 years, so I don't see how you could call it “New Age.” If Valentinian Gnosticism has tenets in common with other popular belief systems, then those would be truths that they all happen to share. That is, the gnosis they may have in common doesn't imply they are historically related to each other. For example, my book–The Gnostic Gospel Illuminated—comes from the Tripartite Tractate of the Nag Hammadi. My retelling of the mythos is just good news for modern man. It is not hermetic; it is not a translation of wisdom from an Egyptian God. It is not New Age. This Gnostic Gospel is simply the story of who we are and where we come from. This is the information A Simple Explanation of the Gnostic Gospel will explain as thoroughly and as simply as possible. The gnosis I am sharing in this book honors God the Father and, as you begin to remember this inherent truth, you will experience a more joyful life. When we use our free will to remember our true inheritance, the God of this universe loses its power to control us. When we turn our eyes upward to the Father, we are freed from the burdens of this world. Once you begin to remember that you are truly loved by our heavenly Father, you will suffer less. When you begin to walk with virtue rather than embracing vice, you will be happier; you will be joyful. Not all of the time. Bad things do happen. But suffering as a response to life's challenges is unnecessary. We are living in a fallen world, and that, I suppose, is another gnostic heresy. For some reason, modern Christians want to insist that this world is blessed by God and is blessedly perfect. But we all know this world we live in isn't perfect, and when you deny that fact you become unduly frustrated and sad , even to the point of depression. Pharmaceuticals are not the solution; gnosis is. One last thing before we leave this introduction. A Simple Explanation of the Gnostic Gospel is not a scholarly, theological tome. Gnosis means knowing. This sort of knowing is not related to book learning. Gnosis refers to remembering what you already know–anamnesis. The point of spiritual study is not to learn new things but to mine what you already possess deep inside of you. When you study new ideas, you must continually weigh the information you are taking in against your own discernment. The purpose of this book is not so much to teach you about Gnosticism; the purpose of this book is to stimulate your own innate gnosis. And there is really only one gnosis that matters in the end, and that is remembering your cosmic origin and the purpose of being alive. Are you familiar with that expression that says, “You can't take it with you”? You can't take it with you usually means that your possessions and your money are worthless to you after you die. People say, “You may as well spend what you have now rather than hoard it, because you can't take it with you,” or, “You should be more generous with your possessions and share them with others, because you can't take it with you.” But aside from money and possessions, another thing you can't take with you is worldly knowledge and book learning. The memes that you pick up here in our material cosmos will not follow you into the afterlife. The only memes that will persist beyond this place and time are those that are compatible with the values of the Pleroma, often referred to as virtues. So you can be a billionaire here in this life, you could be a tech giant and shoot off your own rockets to Mars, you could be President of the United States or the head of a crime syndicate, but you won't have a dime in Heaven. Likewise, you can have three Ivy League degrees but learn nothing of lasting value. Your advanced degrees in religious studies or in physics or archeology are ultimately worthless. The only knowledge of lasting value is the gnosis that transcends this material cosmos. This is the type of knowledge we address in this book: gnosis of the Father and the Son, gnosis of the Pleroma and the Aeons, gnosis of the fall and how to avoid partaking in the fall, gnosis of redemption from the fall, gnosis of the mission of the Christ, and gnosis of the Simple Golden Rule of love and cooperation. More than book learning, what we really need to learn is discernment. Our culture does not promote either critical thinking or discernment. Our culture actually promotes going along to get along. Our culture teaches us to feed our narcissistic egos and denies that we exist beyond our egos. Science officially denies the existence of souls because souls cannot be dissected, weighed, or measured, and science only believes in tangible evidence they can squeeze out of their experiments. You can't tease out a soul in an atom smasher. But here's what I'd like to tell you today: that the academy of scholars don't know much of anything of lasting value. This is because academia only studies “isms” and not gnosis. Academic publications are, for the most part, empty of any sort of gnosis or spiritual discernment. University scholasticism, another ism, scours the writings of other scholars and builds upon officially pre-approved conclusions. This is why the footnotes and the reference sections are so important, because they disclose the limits of the scholar's inquiry. These scholars are not mining the actual source of knowledge. Rather, they are continually adding and stripping wallpaper from the walls of academia and painting over other people's decor in the name of intellectual progress. But it's not progress; it's only an accumulation of essentially useless information. We have no need of knowledge for the sake of knowledge. Knowledge should be used to inform your own gnosis. Knowledge should be weighed by the scales of your own discernment. The purpose of reading, writing, and arithmetic is to aid your own recall of gnosis. The purpose of scholarship, if you want to be a gnostic scholar, is to enhance your practice of gnosis. It is far better to be a gnostic practitioner with little formal education than to be a scholar with little or no gnosis. So go ahead and study, but realize that the study has no value unless it helps you to realize truth, and the only truth you need is Aeonic truth. The vast majority of memes do not lead us to truth. Most memes are forms of delusion, whether you pick them up from worldly culture or soulless universities. Most memes stand between you and your realization of self. In academia, consciousness is largely denied. Some academics go so far as to claim that apparent consciousness is nothing but random nodes in a mathematical abstraction, and that what we think of as ourselves is only packets of information that arise from calculations. Those researchers who are into consciousness studies believe themselves to be at the forefront of uncovering the nature of consciousness through scientific procedure. They are attempting to discover the true nature of consciousness through reductionism and measurements. The consciousness studies articles I have read attempt to reduce consciousness rather than expand it. They believe consciousness can be grasped by going tinier and tinier. That's called scientific reductionism. It reduces the big to the tiny. A Simple Explanation of the Gnostic Gospel is the opposite of reductionism. We keep going larger and larger, all the way up to the gigantic, to the immeasurable, to the level of the Aeons, the Pleroma, the Son, the Christ, and the Father. That's the opposite direction of reductionism. It's going large. So hang onto your hats and let's get ready to mine some very big gnosis. You may purchase my original book, The Gnostic Gospel Illuminated at gnosticinsights.com. It is also available as a pocket edition from lulu.com for only $7. You may purchase A Simple Explanation of the Gnostic Gospel at amazon or even your local independent book store; just ask them to order it for you. It is listed in the Ingram catalog. It is also available in kindle and audible, narrated by Aeon Byte's Miguel Conner. If you have purchased any of the books, please leave a review on amazon.com. We need to raise their profile in the amazon algorithm so others will see the books. Feel free to use the Comments form on the Contact Us page at gnosticinsights.com or the Gnostic Reformation on Substack if you would like to ask any questions. Your ongoing support of this Gnostic Insights podcast is greatly appreciated. Thank you!

“The world is a very volatile place, with currently 110 conflicts globally, and yet healthcare staff in the hospitals, even here in London, are not prepared to be the only clinician who can help in a crisis or hostile setting,” says Dr. David Gough, CEO of the David Nott Foundation, which equips providers with the skills and confidence needed to function in war and other extraordinary situations. A former British Army doctor injured in Afghanistan, Gough brings lived experience as well as a background in tech to his current role at the Foundation, which itself is anchored in decades of field work amassed by its namesake, a renowned war surgeon. As Dr. Gough points out to host Lindsey Smith, the cause could be helped by augmenting medical school curricula, but in the meantime, the Foundation is filling the knowledge gap by using prosthetics, virtual reality simulations and cadavers to train a broad swath of health workers including surgeons, anesthetists, and obstetricians. Tune in to this important Raise the Line conversation as Dr. Gough reflects on the strengths and weaknesses of NGOs in doing this work, his plans to expand the Foundation's footprint in the US, and the gratifying feedback he's received from trainees now operating on the frontlines in Ukraine and elsewhere. Mentioned in this episode:David Nott Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.With monumental movement on 340B rebates, changes in Medicare and Medicaid payments, and evolving audit priorities, 2025 has been a transformative year in the world of 340B. We sit down with 340B Health Senior Manager of Policy and Compliance Rebecca Swartz to chronicle some of the biggest developments of such an eventful year and forecast what to expect in 2026.Rebates Take ShapeSwartz says 2025 will go down as the year that a rebate model shifted from a hypothetical approach pushed by drugmakers into a fully developed model with implementation criteria. The Health Resources & Services Administration (HRSA) approved plans for 340B rebate models set to take effect in January for nine of 10 drugs subject to the 2026 Medicare maximum fair prices. Rebates for the remaining drug on that list will kick in April 1. Swartz discusses how hospitals should prepare for this pilot program, which is set to upend decades of established 340B operations and impose intense financial and logistical burdens on safety-net hospitals nationwide.Medicaid, IRA Changes Set To Impact 340B HospitalsThis year also saw massive changes to Medicaid funding as well as Medicare pay changes under the implementation of the Inflation Reduction Act (IRA). Swartz says these developments are projected to shrink safety-net hospital margins even further. Renewed congressional focus is putting 340B in a high-profile spot, with potentially significant implications for the program and hospitals in the coming months.2026 Tips for HospitalsSwartz says she's identified two areas as more of a focus for HRSA audits this year: expanded scrutiny of offsite and on-site trial balances and the ways covered entities list shipping addresses. To prepare for possible shakeups in 2026, she recommends that covered entities begin and maintain cross-functional planning across departments and closely monitor denials, delays, and other costs from new rebate programs in addition to monitoring wholesale acquisition cost (WAC) changes and contract pharmacy developments.Resources340B Health Year-in-Review Webinar: 2025 Highlights and What's on the Horizon

In this conversation, Madelyn Morris, co-owner of Mickelberry Gardens, shares insights into her journey of creating a honey herbal wellness brand that specializes in oxymels – a tonic made of honey, vinegar, and herbs. She discusses the benefits of oxymels, the importance of sourcing local and organic ingredients, and the value of B Corp certification. Madelyn share their founding story, the challenges they faced in the early years of the business, and what they've been able to accomplish in their 15 years in business. She offers advice for aspiring entrepreneurs, highlighting the importance of passion and adaptability in business, and we wrap up with Madelyn sharing her vision of a better world.Takeaways:Mickelberry Gardens combines honey and herbalism for wellness.Oxymels are a tonic of honey, vinegar, and herbs with roots back to ancient Greece.Natural remedies are increasingly replacing pharmaceuticals.Sourcing local and organic ingredients is crucial for quality.Starting small allows for sustainable growth.B Corp certification provides a framework for improvement.Having a strong business partner can make a big difference.Adapting to change is essential for business longevity.Building a resilient business takes time and effort.A better world is one where all living things thrive.Sound bites:“The word oxymel is from Latin. Oxy is acid and mel is sweet or honey.”“Hippocrates, the father of Western medicine, prescribed oxymels for a wide variety of health concerns.”“Honey and vinegar have amazing health benefits just on their own. And when you combine them, it adds a lot of additional benefits.”“The source of where the honey comes from really matters.”“‘I've noticed in my own garden that bees are really drawn to the medicinal herbs.”“There was something like really magical about harvesting elderberries for the first time.”"It's okay to start small."“We're still manufacturing everything that we sell.”“Just doggedly pursuing it if you really believe in it. Not giving up and continuing to work at it is really the only way you're gonna get there or get anywhere.”"A better world is one that is holistic where all things, even the tiny unseen things, are thriving.”Links:Promo Code: BRANDSFORABETTERWORLD15% off on all oxymel honey tonics, sprays, and skin care from our online shop! www.mickelberrygardens.com…Madelyn Morris on LinkedIn - https://www.linkedin.com/in/madelyn-morris-86642819/Mickelberry Gardens - https://mickelberrygardens.com/ Mickelberry Gardens on LinkedIn - https://www.linkedin.com/company/mickelberry-gardens/Mickelberry Gardens on Facebook - https://www.facebook.com/MickelberryGardens/Mickelberry Gardens on Instagram - https://www.instagram.com/mickelberrygardens/Mickelberry Gardens on YouTube - https://www.youtube.com/@mickelberrygardens2593…Changing Your Mind by Michael Pollan (Book) - https://michaelpollan.com/books/how-to-change-your-mind/…Brands for a Better World Episode Archive - http://brandsforabetterworld.com/Brands for a Better World on LinkedIn - https://www.linkedin.com/company/brand-for-a-better-world/Modern Species - https://modernspecies.com/Modern Species on LinkedIn - https://www.linkedin.com/company/modern-species/Gage Mitchell on LinkedIn - https://www.linkedin.com/in/gagemitchell/…Print Magazine Design Podcasts - https://www.printmag.com/categories/printcast/…Heritage Radio Network - https://heritageradionetwork.org/Heritage Radio Network on LinkedIn - https://www.linkedin.com/company/heritage-radio-network/posts/Heritage Radio Network on Facebook - https://www.facebook.com/HeritageRadioNetworkHeritage Radio Network on X - https://x.com/Heritage_RadioHeritage Radio Network on Instagram - https://www.instagram.com/heritage_radio/Heritage Radio Network on Youtube - https://www.youtube.com/@heritage_radioChapters:03:00 Introduction to Mickelberry Gardens06:09 Understanding Oxymels: The Sweet and Sour Remedy09:02 Product Offerings: Exploring Unique Formulations11:46 Transitioning from Pharmaceuticals to Natural Remedies14:51 The Journey of Starting a Business17:37 The Importance of Local and Organic Sourcing20:55 The Health Benefits of Honey and Its Sources23:59 Lessons Learned in Business Growth26:43 Reflections on Business Strategy and Growth33:56 The Evolution of Business Growth35:45 Current Operations and Challenges38:23 The Importance of Delegation41:37 Manufacturing Control and Revenue Streams43:51 Becoming B Corp Certified47:47 Advice for Aspiring Entrepreneurs53:44 Personal Insights and RecommendationsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

12-19-2025: Wake Up Missouri with Randy Tobler, Stephanie Bell, and Producer Drake

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Servier Pharmaceuticals LLC v. Robert F. Kennedy, Jr.

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this eye-opening episode of The Tudor Dixon Podcast, Tudor sits down with author Aimee Donnellan for a deep dive into the meteoric rise of Ozempic—the diabetes drug turned cultural phenomenon for weight loss. Together, they unpack the surprising science behind GLP-1 medications, the growing trend of microdosing, and the real risks users often overlook. Donnellan and Dixon explore how body image pressures, diet culture, and the powerful food industry fuel America’s obesity crisis. They also discuss why the drug has become both celebrated and controversial, and what its popularity means for the future of weight management.See omnystudio.com/listener for privacy information.

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Norwich Pharmaceuticals, Inc. v. Robert F. Kennedy, Jr.

Norwich Pharmaceuticals, Inc. v. Robert F. Kennedy Jr.

As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we're showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them. Today's spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company's INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies. In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company's mission to create new pathways toward a cancer-free future. Robert explains how Phio's INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio's work. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension. Robert explains, "I feel as though Sparrow has come full circle, actually, with the mechanism of our drug. Originally, we have a drug that targets HSD-1. We can talk about what that is, but it's involved in intracellular cortisol regulation. This was a class of drugs that was originally developed targeting cardiometabolic diseases like type 2 diabetes. And the drugs had some moderate efficacy, but they weren't well differentiated in a broad population and largely were just discontinued for commercial reasons." "Our company was founded a number of years ago based on the idea that these drugs had real potential but hadn't been used in the right patient population. And that being the patient population with the disease that we know is driven by excess cortisol toxicity, because that's aligned with the mechanism, as I was mentioning. So we generated some really interesting data in a rare disease called Endogenous Cushing syndrome. This is a very severe orphan disease with patients who have very severely elevated cortisol, showing in fact that yes, this mechanism does seem like it could have a very major impact in the right patient population." "Simultaneously, another company published some data showing that actually there's a very large population of people with treatment-resistant type 2 diabetes, a very high level of medical need, and that their underlying disease actually is being driven by elevated levels of cortisol. And so when you bring together the data that we generated and what appears to be a large amount needed in a large population, it seems like we may have the perfect solution for that. So we've refocused our efforts on a broad population of treatment-resistant type 2 diabetes in patients whose disease is being impacted or driven by elevated cortisol levels."  #SparrowPharmaceuticals #Type2Diabetes #CardiometabolicDisease #CortisolRegulation #Cortisol #GLP1 #RareDisease sparrowpharma.com Download the transcript here

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension. Robert explains, "I feel as though Sparrow has come full circle, actually, with the mechanism of our drug. Originally, we have a drug that targets HSD-1. We can talk about what that is, but it's involved in intracellular cortisol regulation. This was a class of drugs that was originally developed targeting cardiometabolic diseases like type 2 diabetes. And the drugs had some moderate efficacy, but they weren't well differentiated in a broad population and largely were just discontinued for commercial reasons." "Our company was founded a number of years ago based on the idea that these drugs had real potential but hadn't been used in the right patient population. And that being the patient population with the disease that we know is driven by excess cortisol toxicity, because that's aligned with the mechanism, as I was mentioning. So we generated some really interesting data in a rare disease called Endogenous Cushing syndrome. This is a very severe orphan disease with patients who have very severely elevated cortisol, showing in fact that yes, this mechanism does seem like it could have a very major impact in the right patient population." "Simultaneously, another company published some data showing that actually there's a very large population of people with treatment-resistant type 2 diabetes, a very high level of medical need, and that their underlying disease actually is being driven by elevated levels of cortisol. And so when you bring together the data that we generated and what appears to be a large amount needed in a large population, it seems like we may have the perfect solution for that. So we've refocused our efforts on a broad population of treatment-resistant type 2 diabetes in patients whose disease is being impacted or driven by elevated cortisol levels."  #SparrowPharmaceuticals #Type2Diabetes #CardiometabolicDisease #CortisolRegulation #Cortisol #GLP1 #RareDisease sparrowpharma.com  Listen to the podcast here

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.Some of the most consequential changes for 340B this year came not from Washington D.C., but from statehouses across the country. We speak with Tom O'Donnell, senior vice president of government relations at 340B Health, to recap some of the biggest changes on the state legislative level throughout this year and to preview what might come from the states in 2026.Seven States Enact New Reporting LawsThis year, Colorado, Hawaii, Idaho, Indiana, Ohio, Rhode Island, and Vermont have added new 340B reporting laws, increasing the list of states with such mandates to 10. O'Donnell says the first reporting requirements that Minnesota enacted in 2023 have influenced newer requirements in the other states. He notes hospitals' continuing concerns about the burdens and possible repercussions of focusing on several specific types of reporting data, including breakdowns by payer type and most frequently used drugs.Hybrid Bills Combine Protections With Reporting MandatesFive states that passed new 340B laws in 2025 did so with a twist. Colorado, Hawaii, Maine, Rhode Island, and Vermont passed combination bills with both contract pharmacy protections with new reporting mandates. O'Donnell says he's also concerned that statehouses are shoehorning in amendments to original statutes to ramp up concerning reporting requirements.Model Legislation Could Mean More Debate in 2026While Minnesota has served as a reference for reporting mandates for other states, model legislation from the American Legislative Exchange Council (ALEC) has created more opportunities for state legislators to push proposals that would limit or scrutinize 340B. O'Donnell says this reflects part of the latest efforts from drugmakers to take their 340B priorities to sympathetic lawmakers at the state level, and it underscores the importance of informing and supporting hospitals on how to push back against these bills.Resources:HRSA Approves Novartis's 340B Rebate Pilot ProposalState Policy & Advocacy Communications Resource Center

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Download the transcript here

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Listen to the podcast here

This week, Emilee is joined by Raquel, who shares her extraordinary first pregnancy and sovereign birth at the age of 39.Raquel speaks candidly about the profound transitions she navigated during this time. The death of her mother, leaving her job, moving homes, and entering into the work of congruency, boundaries, and privacy. Choosing a wild pregnancy, she hired a Radical Birth Keeper graduate to hold space as she walked this sacred path.She opens up about the challenges she faced postpartum with nursing and her child's tongue tie, reflecting on what she might do differently now. And she speaks with clarity about her sense of completion after one child, naming that she does not desire more.This conversation carries the archetype of the death of the maiden, a story of initiation, sovereignty, and the power of claiming motherhood on one's own terms.Donate to the podcast here. If you want to connect with Raquel, follow her on Instagram here and you can find her website here.Find more from Emilee on Instagram, YouTube and the Free Birth Society website.Disclaimer: Free Birth Society, LLC of North Carolina shares personal and educational stories and experiences related to freebirth and holistic care. This content is not medical advice, and we are not a licensed midwifery practice. Testimonials reflect individual experiences; results may vary. For services or scheduling, contact info@freebirthsociety.com. See full disclaimer at freebirthsociety.com/youtubeterms.

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Roger McFillin was interviewed by Renaud Beauchard from Tocsin Media—France's leading independent media platform with 30 million monthly views. In this unflinching conversation, Dr. Roger McFillin exposes what he calls a deliberate psychological operation on the American people: a system designed not to heal but to create lifelong customers, sever your connection to God, and make you dependent on medical authority for problems that were never diseases in the first place. The chemical imbalance theory? Born in pharmaceutical marketing rooms, not laboratories. ADHD? A label that stops investigation into the real causes poisoning our children. This isn't incompetence. It's an attack on human consciousness itself. And the first step to freedom is understanding exactly how they did it to you. Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AP's Lisa Dwyer reports on a new deal between the U.S. and the U.K. over pharmaceuticals.

In October, chemical engineer Will Tarpeh was awarded a 2025 MacArthur “Genius Grant” in recognition of his pioneering work to turn wastewater into a source of valuable materials. Will envisions a future in which the concept of wastewater is obsolete, thanks to advances in recycling. A couple of years ago, we sat down to talk with him about this work, and we hope you'll take another listen today to learn more about the research Will is doing to transform the potential of wastewater into resources.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​William Abraham TarpehConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Will Tarpeh, a professor of chemical engineering at Stanford University.(00:03:01) Wastewater as a Modern MineHow elements like nitrogen and phosphorus can be recovered from waste.(00:04:15) Path to Sanitation ResearchWill shares what led to his interest in studying wastewater.(00:06:55) The Science of SeparationThe electrochemical and material techniques to extract valuable compounds.(00:08:37) Urine-Based FertilizerHow human urine could meet up to 30% of global fertilizer needs.(00:11:08) Drugs in WastewaterThe potential of reclaiming pharmaceuticals from waste streams.(00:14:14) Decentralized SanitationOpportunities for neighborhood or household-scale treatment systems.(00:16:48) Source Separation SystemsHow dividing waste at the source improves recycling and recovery.(00:18:56) Global Sanitation ChallengesWays that developing countries can adopt modern waste solutions.(00:23:51) Preventing Algal BloomsThe systems that are helping to reduce nutrient pollution and dead zones.(00:27:16) The Urine SummitA community advancing urine recycling and sustainable sanitation policy.(00:28:43) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this special mini-episode, we invite listeners to help shape the future of the show and enter a drawing for a $100 gift card by participating in our first-ever listener survey. Since launching in May 2020, 340B Insight has released more than 125 episodes featuring conversations with hospital and health system leaders, policy experts, and operations specialists from across the country. Their insights have helped listeners stay informed on the latest developments in 340B and bring practical lessons back to their own organizations.As we plan the next phase of the podcast, we want to hear directly from our listeners. The brief survey asks what draws you to the show, the topics and guests you've found most valuable, and what you'd like us to explore in future episodes. Your input will help ensure the podcast continues to reflect the needs and interests of the 340B community.The survey takes only a few minutes to complete. You may submit your responses anonymously, or you can share your contact information to be entered into a drawing for a $100 gift card. Take the survey by visiting 340bpodcast.org/survey. Thank you for listening and sharing your thoughts!

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast